Hematopoietic Cell Transplantation (HCT)
HCT refers to a procedure in which hematopoietic stem cells are infused to restore bone marrow function in cancer individuals who receive bone-marrow-toxic doses of cytotoxic drugs with or without whole-body radiation therapy. Hematopoietic cells may be obtained from the transplant recipient (autologous HCT) or from a donor (allogeneic HCT).
Allogeneic (HCT) using a myeloablative conditioning regimen may be considered medically necessary to treat ANY of the following conditions:
Allogeneic HCT using a reduced-intensity conditioning regimen may be considered medically necessary as a treatment of AML in individuals who are in complete marrow and extramedullary remission, and who for medical reasons would be unable to tolerate a myeloablative conditioning regimen.
The use of Allogeneic HCT for all other indications is considered not medically necessary.
Autologous HCT may be considered medically necessary to treat AML in first or second remission or relapsed AML if responsive to intensified induction chemotherapy.
The use of autologous HCT for all other indications is considered not medically necessary.